[go: up one dir, main page]

AU2002221129A1 - Triglyceride depressant composition - Google Patents

Triglyceride depressant composition

Info

Publication number
AU2002221129A1
AU2002221129A1 AU2002221129A AU2112902A AU2002221129A1 AU 2002221129 A1 AU2002221129 A1 AU 2002221129A1 AU 2002221129 A AU2002221129 A AU 2002221129A AU 2112902 A AU2112902 A AU 2112902A AU 2002221129 A1 AU2002221129 A1 AU 2002221129A1
Authority
AU
Australia
Prior art keywords
depressant composition
triglyceride
triglyceride depressant
composition
depressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221129A
Inventor
Tatsuhito Kondo
Masato Nakayama
Tsuneoki Ohsawa
Ippei Shimizu
Ikuo Takagi
Yasuhiro Torizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of AU2002221129A1 publication Critical patent/AU2002221129A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002221129A 2000-12-18 2001-12-12 Triglyceride depressant composition Abandoned AU2002221129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000383051 2000-12-18
JP2000-383051 2000-12-18
PCT/JP2001/010912 WO2002049640A1 (en) 2000-12-18 2001-12-12 Triglyceride depressant composition

Publications (1)

Publication Number Publication Date
AU2002221129A1 true AU2002221129A1 (en) 2002-07-01

Family

ID=18850773

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221129A Abandoned AU2002221129A1 (en) 2000-12-18 2001-12-12 Triglyceride depressant composition

Country Status (7)

Country Link
US (2) US20040009986A1 (en)
JP (1) JP4212272B2 (en)
CN (1) CN1307990C (en)
AU (1) AU2002221129A1 (en)
CA (1) CA2432035A1 (en)
TW (1) TWI284529B (en)
WO (1) WO2002049640A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05000050A (en) * 2002-07-03 2005-04-08 Esperion Therapeutics Inc Compositions comprising panthetine for the treatment of dyslipidemia.
JP2005187454A (en) * 2003-12-05 2005-07-14 Sankyo Co Ltd Vitamin e-containing, ldl-reducing agent and/or arteriosclelosis inhibitor composition
US20050192347A1 (en) * 2003-12-23 2005-09-01 Dasseux Jean-Louis H. Urea and thiourea compounds and compositions for cholesterol management and related uses
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
NZ552390A (en) * 2004-08-06 2010-01-29 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
BRPI0514189A (en) * 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc statin pharmaceutical compositions and related treatment methods
KR101112549B1 (en) * 2005-01-31 2012-06-12 삼성전자주식회사 Thin film transistor array panel
CN104799302A (en) * 2014-01-25 2015-07-29 天津中瑞药业股份有限公司 Inositol nicotinate nutrition fortification capsule preparation metho
CN104799269A (en) * 2014-01-25 2015-07-29 天津中瑞药业股份有限公司 Selenium-containing inositol nicotinate nutrition fortification capsule preparation method
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
EP4003317B1 (en) * 2019-07-29 2023-09-20 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
WO2022129003A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Multiparticulate solid oral dosage form comprising statin and vitamin e

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019891B2 (en) * 1978-12-01 1985-05-18 第一製薬株式会社 Drug-induced fatty liver agent
JPS5869813A (en) * 1981-10-23 1983-04-26 Sogo Yatsukou Kk Serum lipid depressant
JPS6041611A (en) * 1983-08-17 1985-03-05 Sankyo Co Ltd Blood lipid improving agent
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US5662934A (en) * 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
JP2618202B2 (en) * 1994-06-23 1997-06-11 株式会社ロッテ Blood lipid lowering agent and food and drink containing it
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US5965621A (en) * 1995-08-17 1999-10-12 Allergan Methods and compositions for reducing or maintaining body weight in a mammal
WO1997038694A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
AU752673B2 (en) * 1997-07-31 2002-09-26 Abbott Laboratories Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
JP2000044470A (en) * 1998-08-04 2000-02-15 Nof Corp Hyperlipidemic drug
CN1092986C (en) * 1999-08-16 2002-10-23 上海本草生物医学工程研究所 CoA oral preparation for reducing blood fat and its preparation method
US6436406B1 (en) * 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
US6916849B2 (en) * 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
AU2002211005A1 (en) * 2000-11-07 2002-05-21 Sankyo Company Limited Lipid peroxide-lowering compositions
WO2002047682A1 (en) * 2000-12-14 2002-06-20 Sankyo Company, Limited Blood lipid ameliorant composition
US7037934B2 (en) * 2000-12-14 2006-05-02 Sankyo Company, Limited Blood lipid ameliorant composition
MXPA05000050A (en) * 2002-07-03 2005-04-08 Esperion Therapeutics Inc Compositions comprising panthetine for the treatment of dyslipidemia.

Also Published As

Publication number Publication date
CN1307990C (en) 2007-04-04
JP2002249431A (en) 2002-09-06
HK1061202A1 (en) 2004-09-10
TWI284529B (en) 2007-08-01
WO2002049640A1 (en) 2002-06-27
JP4212272B2 (en) 2009-01-21
CA2432035A1 (en) 2002-06-27
US20060223811A1 (en) 2006-10-05
CN1489461A (en) 2004-04-14
US20040009986A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001292783A1 (en) Antireflective composition
AU2001271027A1 (en) Ester derivatives
AU2001262847A1 (en) Language-understanding
AU2001282301A1 (en) Fuel composition
AU2001230894A1 (en) Pro-perfume composition
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001220246A1 (en) Neckphone
AU2002241536A1 (en) True-time delay generator
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001233145A1 (en) Dispersant composition
AU2001258349A1 (en) Bisacylguanidine
AU2002221129A1 (en) Triglyceride depressant composition
AU2001274593A1 (en) Cold-setting composition
AU2001241098A1 (en) Composition
AU2001258924A1 (en) Microsatellite-aflp
AU2001275201A1 (en) Acne-treating composition
AU2001246864A1 (en) Hypotensors
AU2001287852A1 (en) Composition
AU2001235764A1 (en) Compositions
AU2001226668A1 (en) Crankshaft-starter-generator
AUPR099200A0 (en) New formulation
AU2002211741A1 (en) Surface modifying composition
AU2001262711A1 (en) Cytoprotectors